CDP 484
Latest Information Update: 27 Sep 2006
At a glance
- Originator Celltech Group; UCB
- Developer Celltech Group
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Interleukin 1 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunological disorders; Inflammation; Rheumatoid arthritis
Most Recent Events
- 26 Sep 2006 Discontinued - Phase-I/II for Rheumatoid arthritis in United Kingdom (SC)
- 26 Sep 2006 Discontinued - Preclinical for Immunological disorders in United Kingdom (SC)
- 26 Sep 2006 Discontinued - Preclinical for Inflammation in United Kingdom (SC)